biotech · Malignant Glioma · Prostate Cancer · CADL
Candel Therapeutics
Candel Therapeutics clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 117 Kendrick Street, Suite 450, Needham, Massachusetts 02494, US
- Founded
- 1999
- Employees
- 82
- Programs
- 12
- Drugs
- 4
- Patents
- 0
Candel Therapeutics projects
5 ClinicalTrials.gov programs sponsored by Candel Therapeutics.
Candel Therapeutics has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Aglatimagene besadenovec
Candel Therapeutics
Borderline Resectable Pancreatic Adenocarcinoma
1 trial -
Aglatimagene besadenovec
Candel Therapeutics
Non Small Cell Lung Cancer
1 trial -
CAN-2409
Candel Therapeutics
Malignant Glioma
1 trial -
aglatimagene besadenovec
Candel Therapeutics
Prostate Cancer
1 trial -
aglatimagene besadenovec + valacyclovir
Candel Therapeutics
Prostate Cancer Patients Treated by Radiotherapy
1 trial
Frequently asked questions
How many clinical projects does Candel Therapeutics have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.